Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Hodgkin Lymphoma
- Lymphoid Leukemia
- Monocytic Leukemia
- Multiple Myeloma
- Myelodysplasia
- Myeloid Leukemia
- Non Hodgkin Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 77 years
- Gender
- Both males and females
Description
Vitamin C is a nutritional supplement that can help fight inflammation. Most patients who have a stem cell transplant have lower than normal levels of vitamin C in their blood. Patients will receive intravenous Vitamin C the day after transplant for two weeks, followed by oral vitamin C until six mo...
Vitamin C is a nutritional supplement that can help fight inflammation. Most patients who have a stem cell transplant have lower than normal levels of vitamin C in their blood. Patients will receive intravenous Vitamin C the day after transplant for two weeks, followed by oral vitamin C until six months after transplant. The effect of the Vitamin C on non-relapse mortality (NRM), time to engraftment, rate of acute graft-versus-host disease and to characterize the safety and tolerability of the vitamin C regimen.
Tracking Information
- NCT #
- NCT03613727
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Gary L Simmons, DO Massey Cancer Center
Get Well Soon